Anticancer activity of released doxorubicin from a folate-mediated polyelectrolyte complex

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• Folate receptor (FR) is overexpressed on various tumor cells, making it a target for cancer therapy.
• Folic acid (FA) exhibits high binding affinity to FR, enabling targeted drug delivery.
• Doxorubicin (DOX) is a potent chemotherapeutic agent, but its efficacy is limited by systemic toxicity.

Purpose of the Study:

• To develop and evaluate folate-mediated nanoparticles for targeted delivery of doxorubicin to FR-positive tumor cells.
• To compare the efficacy of folate-targeted nanoparticles with non-targeted nanoparticles.
• To visualize and confirm the cellular uptake and drug release mechanisms.

Main Methods:

• Synthesis of folate-mediated chondroitin sulfate (FA-PEG-ChS) and non-folate-mediated naproxen-linked chondroitin sulfate (Nap-PEG-ChS) nanoparticles with PEG1000 spacers.
• Encapsulation of doxorubicin (DOX) within chitosan-based polyelectrolyte complexes (PEC).
• Labeling PEC with FITC for imaging and testing on FR-positive KB and FR-deficient A549 cancer cells.

Main Results:

• DOX-loaded FA-complex showed an IC(50) of 1.53 μg/ml, compared to 0.91 μg/ml for free DOX.
• Confocal microscopy confirmed co-internalization of DOX and FITC-labeled nanoparticles into the cytoplasm of KB cells.
• Evidence of gradual DOX release from the nanoparticles within the cancer cells.

Conclusions:

• Folate-mediated nanoparticles effectively target and deliver doxorubicin to FR-positive cancer cells.
• This targeted delivery system demonstrates potential for improved cancer treatment outcomes.
• The study highlights the utility of FA-conjugated nanoparticles for site-specific drug delivery and imaging.